You are here: Industry Insights > ASC42

News List

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication prnasia
January 11, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication.
Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis prnasia
November 15, 2021
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC)...
Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases prnasia
October 14, 2021
Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs...
Ascletis Announces Dosing of the First Cohort of Healthy Subjects in the FXR Agonist ASC42 Bridging Study for Chronic Hepatitis B Indication in China prnasia
July 13, 2021
Ascletis Pharma Inc. today announces the dosing of the first cohort of healthy subjects in the ASC42 bridging study in China for CHB indication.
Gannex Announces Positive Topline Results of the U.S. Phase I Trial of NASH Drug ASC42, an FXR Agonist prnasia
June 17, 2021
Gannex announces positive topline results of safety and pharmacodynamic biomarkers from the U.S. Phase I trial of NASH drug farnesoid X receptor (FXR) agonist ASC42.
Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication prnasia
June 07, 2021
Ascletis Pharma Inc. today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for chronic hepatitis B (CHB) indication.
Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication prnasia
May 27, 2021
Gannex today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its drug candidate ASC42 to conduct clinical trials for NASH indication.
First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial prnasia
December 28, 2020
Gannex announces today dosing of first subject with its NASH drug candidate ASC42, a Farnesoid X Receptor (FXR) agonist, in a U.S. Phase I Trial.
Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist prnasia
October 16, 2020
Gannex Pharma Co. announces today that it received investigational new drug application (IND) approval from FDA for its drug candidate ASC42, to conduct clinical trials for non-alcoholic steatohepatitis (NASH) indication.
Gannex receives US IND Approval for NASH drug candidate, an FXR agonist expresspharma
October 14, 2020
In two NASH animal models, ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis.